Two non-psychoactive cannabis compounds, cannabidiol (CBD) and cannabigerol (CBG), could offer new treatment options for metabolic dysfunction-associated steatotic liver disease (MASLD), according to research published in…
Ananda Pharma has cleared the final regulatory hurdle needed to begin its ENDOCAN Phase 2 clinical trial, receiving approval from the MHRA and NHS Health Research…